Open AccessPlasma 8-hydroxy-2′-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10
Author(s) -
Kevin Biglan,
E. Ray Dorsey,
Rebecca Evans,
Christopher A. Ross,
Steven M. Hersch,
Ira Shoulson,
Wayne R. Matson,
Karl Kieburtz
Publication year - 2012
Publication title -
journal of huntington's disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.081
H-Index - 24
eISSN - 1879-6400
pISSN - 1879-6397
DOI - 10.3233/jhd-2012-120007
Subject(s) - coenzyme q10 , deoxyguanosine , medicine , cohort , gastroenterology , endocrinology , chemistry , oxidative stress
We analyzed plasma 8OHdG concentrations in 20 individuals enrolled in the Pre-2CARE study before and after treatment with CoQ. Treatment resulted in a mean reduction in 8OHdG of 2.9 ± 2.9 pg/ml for the cohort (p = 0.0003) and 3.0 ± 2.6 pg/ml, for the HD group (p = 0.002). Baseline 8OHdG levels were not different between individuals with HD and controls (19.3 ± 3.2 pg/ml vs. 19.5 ± 4.7 pg/ml, p = 0.87) though baseline CoQ levels were elevated in HD compared with controls (p < 0.001). CoQ treatment reduces plasma 8OHdG and this reduction may serve as a marker of pharmacologic activity of CoQ in HD.